0000914475-24-000138.txt : 20240521
0000914475-24-000138.hdr.sgml : 20240521
20240521173530
ACCESSION NUMBER: 0000914475-24-000138
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240517
FILED AS OF DATE: 20240521
DATE AS OF CHANGE: 20240521
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sharp Shalini
CENTRAL INDEX KEY: 0001377202
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-22705
FILM NUMBER: 24970909
MAIL ADDRESS:
STREET 1: C/O ULTRAGENYX PHARMACEUTICAL INC.
STREET 2: 60 LEVERONI COURT
CITY: NOVATO
STATE: CA
ZIP: 94949
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC
CENTRAL INDEX KEY: 0000914475
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 330525145
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6027 EDGEWOOD BEND COURT
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: (858) 617-7600
MAIL ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
4
1
wk-form4_1716327316.xml
FORM 4
X0508
4
2024-05-17
0
0000914475
NEUROCRINE BIOSCIENCES INC
NBIX
0001377202
Sharp Shalini
12780 EL CAMINO REAL
SAN DIEGO
CA
92130
1
0
0
0
1
Common Stock
2024-05-17
4
M
0
2100
0
A
2100
D
Common Stock
2024-05-17
4
S
0
1106
141.9018
D
994
D
Restricted Stock Unit
2024-05-17
4
M
0
2100
0
D
Common Stock
2100
0
D
The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $140.81 to $142.33. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range
Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.
This RSU award was granted to the Reporting Person on May 17, 2023 and is fully vested.
/s/ Darin Lippoldt, Attorney-in-Fact
2024-05-21